Oregon Public Employees Retirement Fund reduced its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 28.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 172,568 shares of the biopharmaceutical company’s stock after selling 67,828 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Bristol-Myers Squibb were worth $9,305,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wills Financial Group Inc. boosted its position in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Wills Financial Group Inc. now owns 3,509 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 10 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,353 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 12 shares in the last quarter. TRUE Private Wealth Advisors boosted its position in shares of Bristol-Myers Squibb by 0.3% in the second quarter. TRUE Private Wealth Advisors now owns 5,377 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 15 shares in the last quarter. Bruderman Asset Management LLC boosted its position in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Bruderman Asset Management LLC now owns 4,258 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 15 shares in the last quarter. Finally, Stillwater Investment Management LLC boosted its position in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Stillwater Investment Management LLC now owns 3,467 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 16 shares in the last quarter. Hedge funds and other institutional investors own 68.84% of the company’s stock.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.4434% during midday trading on Wednesday, reaching $56.6099. The company’s stock had a trading volume of 4,301,453 shares. The firm has a market capitalization of $94.61 billion, a PE ratio of 28.3191 and a beta of 0.90. The stock has a 50 day moving average of $52.72 and a 200 day moving average of $62.87. Bristol-Myers Squibb Co. has a 52 week low of $49.03 and a 52 week high of $77.12.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.12. The business had revenue of $4.83 billion for the quarter, compared to analyst estimates of $4.76 billion. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The company’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.39 earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co. (BMY) Shares Sold by Oregon Public Employees Retirement Fund” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/30/bristol-myers-squibb-co-bmy-shares-sold-by-oregon-public-employees-retirement-fund.html.

A number of analysts recently commented on BMY shares. Credit Suisse Group AG cut Bristol-Myers Squibb from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $86.00 to $63.00 in a research report on Sunday, August 7th. Leerink Swann reiterated an “outperform” rating and set a $69.00 price objective on shares of Bristol-Myers Squibb in a research report on Sunday, October 9th. Morgan Stanley reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Thursday, August 25th. Jefferies Group reiterated a “hold” rating and set a $57.00 price objective (down previously from $69.00) on shares of Bristol-Myers Squibb in a research report on Monday, September 12th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and set a $75.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, September 27th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $67.51.

In other news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $56.87, for a total value of $1,228,392.00. Following the transaction, the director now owns 334,499 shares in the company, valued at $19,022,958.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.